Reaction
Chronic Myeloid Leukaemia Recurrent reporting signals
As of the last recalculation, Chronic Myeloid Leukaemia Recurrent appears in 541 FAERS reports alongside 9 co-occurring drug terms. The strongest observed disproportionality signal is IMATINIB (PRR 423.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Imatinib | 143 | 423.7 | 427.1 |
| Nilotinib | 194 | 394.0 | 396.7 |
| Dasatinib | 95 | 119.1 | 119.4 |
| Bosutinib | 22 | 98.2 | 98.4 |
| Imatinib Mesylate | 33 | 48.4 | 48.5 |
| Hydroxyurea | 19 | 35.8 | 35.8 |
| Busulfan | 13 | 32.5 | 32.6 |
| Blinatumomab | 8 | 29.9 | 29.9 |
| Fludarabine Phosphate | 24 | 24.5 | 24.5 |